# Apellis Pharmaceuticals, Inc.: Form D filings

Apellis Pharmaceuticals, Inc., a pharmaceuticals company in Crestwood, KY, filed 11 Form D notices with the SEC between 2010 and 2017. The latest, on August 17, 2017, reports $20 million sold of a $60.1 million offering to 16 investors.

Find out what Apellis Pharmaceuticals, Inc. does, who founded it and who invested, beyond what the filing says. $10 of credit on sign-up, no card.

- [Watch for new raises](https://specstream.ai/workspace/ask?q=Tell%20me%20when%20Apellis%20Pharmaceuticals%2C%20Inc.%20files%20a%20new%20Form%20D%20or%20reports%20more%20money%20sold%2C%20with%20the%20filing&src=data-formd&kind=alert&entity=Apellis%20Pharmaceuticals%2C%20Inc.&page=%2Fdata%2Fform-d%2Fcompany%2Fapellis-pharmaceuticals-inc-1492422)
- [Get founders and investors](https://specstream.ai/workspace/ask?q=For%20Apellis%20Pharmaceuticals%2C%20Inc.%2C%20find%20what%20the%20company%20does%2C%20its%20website%2C%20the%20founders%20and%20executives%20with%20their%20LinkedIn%20and%20work%20email%2C%20its%20investors%20and%20every%20funding%20round%20with%20the%20amounts%2C%20its%20headcount%20and%20any%20reported%20valuation&src=data-formd&kind=record&entity=Apellis%20Pharmaceuticals%2C%20Inc.&page=%2Fdata%2Fform-d%2Fcompany%2Fapellis-pharmaceuticals-inc-1492422)

## The full lists

This record is a row of these lists. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (company, CIK, year incorporated, street, city, state and 5 more), which open on your screen as soon as the payment clears and come by email.

- [Form D filings in Kentucky](https://specstream.ai/data/form-d/state/kentucky): 216 rows, by operating companies, filed since November 1, 2024, $10.80, or the new rows each week for $19 a month. Buy: https://specstream.ai/data/form-d/state/kentucky
- [Form D filings in Pharmaceuticals](https://specstream.ai/data/form-d/industry/pharmaceuticals): 346 rows, by operating companies, filed since November 1, 2024, $17.30, or the new rows each week for $19 a month. Buy: https://specstream.ai/data/form-d/industry/pharmaceuticals

SpecStream is the live web data engine for teams and agents. It reads every Form D on SEC EDGAR the day it is filed, and this page is that reading. Ask for your own cut (a state, an industry, a size) and new filings arrive in your sheet, CRM, Slack or agent as they land.

## Company details from the filing

- Address: 6400 WESTWIND WAY, SUITE A, Crestwood, KY, 40014
- Phone: (502) 241-4114
- Industry: Pharmaceuticals
- Entity type: Corporation
- Incorporated in: Delaware
- Revenue range: Decline to Disclose
- Exemptions claimed: Rule 506(b)
- SEC identifier (CIK): 1492422

## Form D filings

| Filed | Type | Offering | Sold | Remaining | Investors | First sale | Filing |
| --- | --- | --- | --- | --- | --- | --- | --- |
| Aug 17, 2017 | New notice | $60,099,974 | $20,033,322 | $40,066,652 | 16 | Aug 7, 2017 | [sec.gov](https://www.sec.gov/Archives/edgar/data/1492422/000149242217000001/0001492422-17-000001-index.htm) |
| Feb 8, 2016 | New notice | $47,135,951 | $47,135,951 | $0 | 7 | Dec 24, 2015 | [sec.gov](https://www.sec.gov/Archives/edgar/data/1492422/000149242216000003/0001492422-16-000003-index.htm) |
| Jan 6, 2016 | New notice | $32,135,952 | $32,135,952 | $0 | 6 | Dec 24, 2015 | [sec.gov](https://www.sec.gov/Archives/edgar/data/1492422/000149242216000001/0001492422-16-000001-index.htm) |
| Jun 9, 2015 | Amendment | $17,732,150 | $17,732,150 | $0 | 1 | Dec 5, 2014 | [sec.gov](https://www.sec.gov/Archives/edgar/data/1492422/000162997015000002/0001629970-15-000002-index.htm) |
| Dec 17, 2014 | New notice | $21,500,000 | $6,000,000 | $15,500,000 | 1 | Dec 5, 2014 | [sec.gov](https://www.sec.gov/Archives/edgar/data/1492422/000091195914000033/0000911959-14-000033-index.htm) |
| Aug 27, 2014 | Amendment | $24,000,000 | $17,842,487 | $6,157,513 | 25 | Jul 30, 2013 | [sec.gov](https://www.sec.gov/Archives/edgar/data/1492422/000149242214000003/0001492422-14-000003-index.htm) |
| Aug 5, 2013 | New notice | $8,000,000 | $6,000,000 | $2,000,000 | 1 | Jul 30, 2013 | [sec.gov](https://www.sec.gov/Archives/edgar/data/1492422/000091195913000035/0000911959-13-000035-index.htm) |
| Jul 25, 2012 | New notice | $3,000,000 | $692,995 | $2,307,005 | 9 | Jul 18, 2012 | [sec.gov](https://www.sec.gov/Archives/edgar/data/1492422/000091195912000024/0000911959-12-000024-index.htm) |
| Jun 20, 2011 | Amendment | $4,213,000 | $2,967,500 | $1,245,500 | 15 | May 20, 2011 | [sec.gov](https://www.sec.gov/Archives/edgar/data/1492422/000091195911000012/0000911959-11-000012-index.htm) |
| Jun 1, 2011 | New notice | $4,213,000 | $1,688,500 | $2,524,500 | 11 | May 20, 2011 | [sec.gov](https://www.sec.gov/Archives/edgar/data/1492422/000091195911000010/0000911959-11-000010-index.htm) |
| May 21, 2010 | New notice | $6,000,000 | $1,700,000 | $4,300,000 | 6 | May 21, 2010 | [sec.gov](https://www.sec.gov/Archives/edgar/data/1492422/000091195910000017/0000911959-10-000017-index.htm) |

## Executive officers and directors named in the filing

| Name | Role | Note in the filing |
| --- | --- | --- |
| Bihua Sinclair Chen | Director |  |
| Steven Sinclair Axon | Executive Officer |  |
| Alec Sinclair Machiels | Director |  |
| Stephanie Sinclair O'Brien | Director |  |
| Robert Sinclair Adelman | Director |  |
| Nicole Sinclair Perry | Executive Officer |  |
| Maha Sinclair Katabi | Director |  |
| Gerald Sinclair Chan | Director |  |
| A. Sinclair Dunlop | Director |  |
| Daniel Sinclair Geffken | Executive Officer |  |
| Cedric Francois | Executive Officer, Director |  |
| Pascal Deschatelets | Executive Officer |  |
| David Sinclair Watson | Executive Officer |  |
| Robert Sinclair Kim | Executive Officer |  |

[Every Form D from the week of Aug 14, 2017](https://specstream.ai/data/form-d/week/2017-08-14) · [All recent filings in Kentucky](https://specstream.ai/data/form-d/state/kentucky) · [All recent Pharmaceuticals filings](https://specstream.ai/data/form-d/industry/pharmaceuticals)

Read from SEC EDGAR. Amount sold is what Apellis Pharmaceuticals, Inc. reported on the day it filed; on an offering that is still open, a later amendment can raise it. Free to reuse with credit to SpecStream under [CC BY 4.0](https://creativecommons.org/licenses/by/4.0/).